Adma Biologics reported $390.32M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Adma Biologics USD 390.32M 86.99M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Novavax USD -144.76M 17.01M Mar/2026
Omeros USD -228.68M 15.13M Jun/2025
Takeda JPY 7.77T 129.5B Mar/2026